Cell & gene therapy supply chains are inherently complex, requiring the utmost attention to quality, cold chain logistics, and chain of custody requirements. As these novel therapeutics demonstrate efficacy and feasibility of implementation in health systems worldwide, innovators are expanding their targets to include new therapeutic areas, and more and more often acute indications. These indications require a new, more dynamic distribution model to ensure that drug reaches patient at the right time, with the same requirement of flawless execution in order to maintain quality standards.

Join Thermo Fisher Scientific and Pluristem Therapeutics as we discuss lessons learned in developing the just-in-time supply chain for their phase III hip fracture study, and how these lessons are being used in their current efforts to treat severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome (ARDS) in the United States.